{"categoria": "NULL", "sottotitolo": "\r\n    \r\n", "testo": "gilead sciences inc nasda$1$2gild announced today its results of \r\n      operations for the first quarter ended march 31 2019 the financial \r\n      results that follow represent year over year comparison of the first \r\n      quarter 2019 to the first quarter 2018 total revenues were $53 billion \r\n      in 2019 compared to $51 billion in 2018 net income was $20 billion or \r\n      $154 per diluted share in 2019 compared to $15 billion or $117 per \r\n      diluted share in 2018 non gaap net income was $23 billion or $176 per \r\n      diluted share in 2019 compared to $20 billion or $148 per diluted \r\n      share in 2018\r\n    \r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          three months ended\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions except per share amounts\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          product sales\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5200\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5001\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          royalty contract and other revenues\r\n        \r\n        \r\n        \r\n        \r\n          81\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          87\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total revenues\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5281\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5088\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net income attributable to gilead\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1975\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1538\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap net income\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          2258\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1958\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          diluted earnings per share\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          154\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          117\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap diluted earnings per share\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          176\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          148\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\nproduct sales\r\n    \r\n\r\n    \r\n\r\n      total product sales for the first quarter of 2019 were $52 billion \r\n      compared to $50 billion for the same period in 2018 product sales for \r\n      the first quarter of 2019 were $38 billion in the united states $882 \r\n      million in europe and $522 million in other locations product sales for \r\n      the first quarter of 2018 were $35 billion in the united states $10 \r\n      billion in europe and $469 million in other locations\r\n    \r\n    \r\n\r\n      ___________________________________\r\n    \r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          note:\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          non gaap financial information excludes acquisition related \r\n          up front collaboration stock based compensation and other expenses \r\n          fair value adjustments of equity securities and discrete tax charges \r\n          or benefits associated with changes in tax related laws and \r\n          guidelines reconciliation between gaap and non gaap financial \r\n          information is provided in the tables on pages 8 through 10\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\nhiv product sales were $36 billion for the \r\n        first quarter of 2019 compared to $32 billion for the same period in \r\n        2018 the increase was primarily driven by higher sales volume as \r\n        result of the continued uptake of biktarvy\u00ae bictegravir 50 \r\n        mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg\r\n      \r\n      \r\n\r\n        \r\nchronic hepatitis c virus hcv product sales were $790 million \r\n        for the first quarter of 2019 compared to $10 billion for the same \r\n        period in 2018 the decline was primarily to lower patient starts \r\n        and competitive dynamics including decline in price in us \r\n        medicare in 2019\r\n      \r\n      \r\n\r\n        \r\nyescarta\u00ae axicabtagene ciloleucel which \r\n        was approved in the united states in october 2017 and europe in august \r\n        2018 generated $96 million in sales during the first quarter of 2019 \r\n        compared to $40 million for the same period in 2018 the increase was \r\n        driven by an increase in the number of therapies provided to patients\r\n      \r\n      \r\n\r\n        other product sales which include products from gilead\u2019s chronic \r\n        hepatitis b virus hbv cardiovascular oncology and other categories \r\n        inclusive of vemlidy\u00ae tenofovir alafenamide 25 mg viread\u00ae \r\n        tenofovir disoproxil fumarate 300 mg letairis\u00ae \r\n        ambrisentan 5 mg and 10 mg ranexa\u00ae ranolazine 500 mg \r\n        and 1000 mg zydelig\u00ae idelalisib 150 mg and ambisome\u00ae \r\n        amphotericin b liposome for injection 50 mg/vial were $696 million \r\n        for the first quarter of 2019 compared to $745 million for the same \r\n        period in 2018 the decrease was primarily to the expected decline \r\n        in ranexa sales after generic entry in the first quarter of 2019\r\n      \r\n    \r\n\r\n    \r\n\r\n      \r\noperating expenses\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          three months ended\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          research and development expenses r&d\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1057\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          937\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap r&d expenses\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          871\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          814\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          selling general and administrative expenses sg&a\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1030\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          997\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap sg&a expenses\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          962\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          884\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      during the first quarter of 2019 compared to the same period in 2018:\r\n    \r\n    \r\n\r\n      \r\n\r\n        r&d expenses increased primarily to up front collaboration \r\n        expenses and higher investments to support gilead\u2019s cell therapy \r\n        programs partially offset by lower stock based compensation expense \r\n        stock based compensation expense was higher for the first quarter of \r\n        2018 following the acquisition of kite pharma inc kite\r\n      \r\n      \r\n\r\n        non gaap r&d expenses increased primarily to higher investments to \r\n        support gilead\u2019s cell therapy programs\r\n      \r\n      \r\n\r\n        sg&a expenses increased primarily to higher promotional expenses \r\n        in the united states and expenses associated with the expansion of \r\n        gilead\u2019s products in europe and japan partially offset by lower \r\n        stock based compensation expense stock based compensation expense was \r\n        higher for the first quarter of 2018 following the acquisition of kite\r\n      \r\n      \r\n\r\n        non gaap sg&a expenses increased primarily to higher promotional \r\n        expenses in the united states and expenses associated with the \r\n        expansion of gilead\u2019s products in europe and japan\r\n      \r\n    \r\n\r\n    \r\n\r\n      \r\neffective tax rate\r\n    \r\n\r\n    \r\n\r\n      the effective tax rate and non gaap effective tax rate in the first \r\n      quarter of 2019 were 163% and 167% compared to 243% and 228% for the \r\n      same period in 2018 respectively the decreases were primarily to \r\n      favorable settlements with taxing authorities for the full year 2019 \r\n      gilead reiterates its effective tax rate guidance and non gaap effective \r\n      tax rate guidance to be in the range of\u00a0215%   225% and 200%   210% \r\n      respectively\r\n    \r\n    \r\n\r\n      \r\ncash cash equivalents and marketable debt \r\n      securities\r\n    \r\n\r\n    \r\n\r\n      as of march 31 2019 gilead had $301 billion of cash cash equivalents \r\n      and marketable debt securities compared to $315 billion as of december \r\n      31 2018 during the first quarter of 2019 gilead generated $14 \r\n      billion in operating cash flow repaid $750 million of debt paid cash \r\n      dividends of $817 million and utilized $834 million on stock repurchases\r\n    \r\n    \r\n\r\n      \r\nfull year 2019 guidance reiterated\r\n    \r\n\r\n    \r\n\r\n      gilead reiterates its full year 2019 guidance initially provided on \r\n      february 4 2019 the guidance for product sales reflects the \r\n      anticipated entry of generic versions of letairis and ranexa in the \r\n      united states and the full year impact of generic products containing \r\n      tenofovir disoproxil fumarate in certain european countries\r\n    \r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions except percentages and per share amounts\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          initially provided\r\n\r\nfebruary 4 2019\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net product sales\r\n        \r\n        \r\n        \r\n        \r\n          $21300   $21800\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap\r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          product gross margin\r\n        \r\n        \r\n        \r\n        \r\n          85%   87%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          r&d expenses\r\n        \r\n        \r\n        \r\n        \r\n          $3600   $3800\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          sg&a expenses\r\n        \r\n        \r\n        \r\n        \r\n          $3900   $4100\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          effective tax rate\r\n        \r\n        \r\n        \r\n        \r\n          200%   210%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          diluted eps impact of acquisition related up front collaboration \r\n          stock based compensation and other expenses\r\n        \r\n        \r\n        \r\n        \r\n          $140   $150\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\ncorporate highlights including the \r\n      announcement of:\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        hepconnect five year multi million dollar initiative aimed at \r\n        addressing the sharp increase in chronic hcv infections fueled by the \r\n        nation\u2019s opioid crisis in partnership with the harm reduction \r\n        coalition and local organizations the initiative will support \r\n        evidence based solutions to meet the needs of people most affected by \r\n        the opioid crisis in indiana kentucky north carolina tennessee and \r\n        west virginia\r\n      \r\n      \r\n\r\n        the departure of alessandro riva md executive vice president \r\n        oncology therapeutics who left gilead to become ceo of another \r\n        pharmaceutical company\r\n      \r\n      \r\n\r\n        the gilead hiv age positively initiative which will provide $176 \r\n        million in grants to 30 organizations in the united states this \r\n        effort aims to enhance the lives of individuals aging with hiv by \r\n        focusing in three priority area$1$2improving care coordination \r\n        increasing resources for better well being and educating and informing \r\n        policies that impact people living and aging with hiv\r\n      \r\n    \r\n\r\n    \r\n\r\n      \r\nproduct and pipeline updates including the \r\n      announcement of:\r\n    \r\n\r\n    \r\n\r\n      \r\ninflammation program\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        week 24 results of finch 1 an ongoing randomized double blind \r\n        placebo  and active controlled phase 3 study of filgotinib an \r\n        investigational oral selective jak1 inhibitor in adults with \r\n        moderately to severely active rheumatoid arthritis ra finch 1 \r\n        evaluated filgotinib versus adalimumab or placebo on stable \r\n        background dose of methotrexate in patients with prior inadequate \r\n        response to methotrexate the study achieved its primary endpoint for \r\n        both doses of filgotinib in the proportion of patients achieving an \r\n        american college of rheumatology 20% response acr20 compared to \r\n        placebo at week 12\r\n      \r\n      \r\n\r\n        week 24 results of finch 3 an ongoing randomized double blind \r\n        active controlled phase 3 study of filgotinib in adults with \r\n        moderately to severely active ra finch 3 evaluated filgotinib in \r\n        combination with methotrexate mtx and as monotherapy in mtx na\u00efve \r\n        patients the study achieved its primary endpoint in the proportion of \r\n        patients achieving an acr20 response at week 24 the proportion of \r\n        patients achieving the primary endpoint of acr20 response at week 24 \r\n        was significantly higher for filgotinib 200 mg plus mtx and filgotinib \r\n        100 mg plus mtx compared with mtx alone\r\n      \r\n      \r\n\r\n        interim safety information from four studies of filgotinib for the \r\n        treatment of ra the data include 24 week results of the ongoing phase \r\n        3 finch 1 2 and 3 trials and updated week 156 safety data from the \r\n        phase 2b darwin 3 long term extension study in patients with ra\r\n      \r\n    \r\n\r\n    \r\n\r\n      \r\nhiv and liver diseases programs\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        data from gilead\u2019s research and development programs in nonalcoholic \r\n        steatohepatitis nash primary sclerosing cholangitis and viral \r\n        hepatitis presented at the international liver congress\u2122 2019 in \r\n        vienna austria these data reflect gilead\u2019s ongoing focus and \r\n        commitment to advancing research and patient care across the field of \r\n        liver disease\r\n      \r\n      \r\n\r\n        approval by japan\u2019s ministry of health labour and welfare mhlw of \r\n        biktarvy for the treatment of hiv 1 infection\r\n      \r\n      \r\n\r\n        the presentation of data at the 2019 conference on retroviruses and \r\n        opportunistic infections which included:\r\n\r\n        \r\n          \r\n\r\n            results from the discover trial two year phase 3 randomized \r\n            controlled double blind study evaluating the safety and efficacy \r\n            of the investigational use of once daily descovy\u00ae \r\n            emtricitabine 200 mg/tenofovir alafenamide 25 mg for hiv \r\n            pre exposure prophylaxis prep compared with truvada\u00ae \r\n            emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg \r\n            for prep in men who have sex with men and transgender women at \r\n            risk for sexually acquired hiv infection in the trial descovy \r\n            achieved the primary efficacy endpoint and demonstrated \r\n            non inferiority to truvada statistically significant advantages \r\n            with respect to bone and renal laboratory parameters were observed \r\n            for participants receiving descovy as compared with those \r\n            receiving truvada\r\n          \r\n          \r\n\r\n            results from phase 2/3 study at 48 weeks evaluating the \r\n            efficacy and safety of biktarvy in virologically suppressed \r\n            adolescents and children at least 6 years of age who are living \r\n            with hiv\r\n          \r\n          \r\n\r\n            results from two studies evaluating the resistance profile of \r\n            biktarvy in virologically suppressed adults switching from \r\n            dolutegravir/abacavir/lamivudine or boosted protease \r\n            inhibitor based regimen for the treatment of hiv 1\r\n          \r\n          \r\n\r\n            results from two studies that support the further development of \r\n            gs 6207 an investigational novel selective first in class \r\n            inhibitor of hiv 1 capsid function for potential future use as \r\n            part of long acting hiv combination therapy interim blinded data \r\n            from phase 1 study in healthy trial participants demonstrated \r\n            that single doses of gs 6207 of up to 450 mg administered \r\n            subcutaneously achieved sustained concentration levels and were \r\n            well tolerated\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        results from stellar 4 phase 3 randomized double blind \r\n        placebo controlled study evaluating the safety and efficacy of \r\n        selonsertib an investigational once daily oral inhibitor of \r\n        apoptosis signal regulating kinase 1 in patients with compensated \r\n        cirrhosis f4 to nash did not meet the pre specified week 48 \r\n        primary endpoint of  1 stage histologic improvement in fibrosis \r\n        without worsening of nash\r\n      \r\n      \r\n\r\n        approval by japan\u2019s mhlw of epclusa\u00ae sofosbuvir 400 \r\n        mg/velpatasvir 100 mg for adults with chronic hcv infection with \r\n        decompensated cirrhosis and for patients with chronic hcv infection \r\n        without cirrhosis or with compensated cirrhosis who have had prior \r\n        treatment with direct acting antiviral therapy\r\n      \r\n      \r\n\r\n        licensing agreement and collaboration agreement with yuhan corporation \r\n        to co develop novel therapeutic candidates for the treatment of \r\n        advanced fibrosis to nash\r\n      \r\n    \r\n\r\n    \r\n\r\n      \r\nnon gaap financial information\r\n    \r\n\r\n    \r\n\r\n      the information presented in this document has been prepared in \r\n      accordance with us generally accepted accounting principles gaap \r\n      unless otherwise noted as non gaap management believes non gaap \r\n      information is useful for investors when considered in conjunction with \r\n      gilead\u2019s gaap financial information because management uses such \r\n      information internally for its operating budgeting and financial \r\n      planning purposes non gaap information is not prepared under \r\n      comprehensive set of accounting rules and should only be used to \r\n      supplement an understanding of gilead\u2019s operating results as reported \r\n      under gaap non gaap measures may be defined and calculated differently \r\n      by other companies in the same industry reconciliation between gaap \r\n      and non gaap financial information is provided in the tables on pages 8 \r\n      through 10\r\n    \r\n    \r\n\r\n      \r\nconference call\r\n    \r\n\r\n    \r\n\r\n      at 4:30 pm eastern time today gilead\u2019s management will host \r\n      conference call and simultaneous webcast to discuss the company\u2019s \r\n      financial results for the first quarter 2019 and provide business \r\n      update the live webcast of the call can be accessed at gilead\u2019s \r\n      investor page at http://investorsgileadcom/ \r\n      please connect to gilead\u2019s website at least 15 minutes prior to the \r\n      start of the call to allow adequate time for any software download that \r\n      may be required to listen to the webcast alternatively please call \r\n      877 359 9508 us or 224 357 2393 international and dial the \r\n      conference id 5259422 to access the call telephone replay will be \r\n      available approximately two hours after the call through 8:00 pm \r\n      eastern time may 4 2019 to access the replay please call \r\n      855 859 2056 us or 404 537 3406 international and dial the \r\n      conference id 5259422 the webcast will be archived on wwwgileadcom \r\n      for one year\r\n    \r\n    \r\n\r\n      \r\nabout gilead sciences\r\n    \r\n\r\n    \r\n\r\n      gilead sciences inc is research based biopharmaceutical company that \r\n      discovers develops and commercializes innovative medicines in areas of \r\n      unmet medical need the company strives to transform and simplify care \r\n      for people with life threatening illnesses around the world gilead has \r\n      operations in more than 35 countries worldwide with headquarters in \r\n      foster city california\r\n    \r\n    \r\n\r\n      \r\nforward looking statement\r\n    \r\n\r\n    \r\n\r\n      statements included in this press release that are not historical in \r\n      nature are forward looking statements within the meaning of the private \r\n      securities litigation reform act of 1995 gilead cautions readers that \r\n      forward looking statements are subject to certain risks and \r\n      uncertainties that could cause actual results to differ materially \r\n      these risks and uncertainties includ$1$2gilead\u2019s ability to achieve its \r\n      anticipated full year 2019 financial results; gilead\u2019s ability to \r\n      sustain growth in revenues for its antiviral and other programs; the \r\n      risk that private and public payers may be reluctant to provide or \r\n      continue to provide coverage or reimbursement for new products; \r\n      austerity measures in european countries that may increase the amount of \r\n      discount required on gilead\u2019s products; an increase in discounts \r\n      chargebacks and rebates to ongoing contracts and future negotiations \r\n      with commercial and government payers; larger than anticipated shift \r\n      in payer mix to more highly discounted payer segments and geographic \r\n      regions and decreases in treatment duration; availability of funding for \r\n      state aids drug assistance programs adaps; continued fluctuations in \r\n      adap purchase driven by federal and state grant cycles as well as \r\n      purchase by retail pharmacies and other non wholesaler locations with \r\n      whom we have inventory management agreements may not mirror patient \r\n      demand and may cause fluctuations in gilead\u2019s earnings; market share and \r\n      price erosion caused by the introduction of generic versions of our \r\n      products; an uncertain global macroeconomic environment; potential \r\n      amendments to the affordable care act or other government action that \r\n      could have the effect of lowering prices or reducing the number of \r\n      insured patients; gilead\u2019s ability to initiate clinical trials in its \r\n      currently anticipated timeframes; the levels of inventory held by \r\n      wholesalers and retailers which may cause fluctuations in gilead\u2019s \r\n      earnings; gilead\u2019s ability to realize the potential benefits of \r\n      collaborations including with yuhan corporation; gilead\u2019s ability to \r\n      submit new drug applications for new product candidates in the timelines \r\n      currently anticipated; gilead\u2019s ability to receive regulatory approvals \r\n      in timely manner or at all for new and current products; gilead\u2019s \r\n      ability to successfully commercialize its products including yescarta; \r\n      the risk that physicians and patients may not see advantages of these \r\n      products over other therapies and may therefore be reluctant to \r\n      prescribe the products; safety and efficacy data from clinical studies \r\n      may not warrant further development of gilead\u2019s product candidates \r\n      including filgotinib selonsertib and gs 6207; gilead\u2019s ability to pay \r\n      dividends or complete its share repurchase program to changes in its \r\n      stock price corporate or other market conditions; fluctuations in the \r\n      foreign exchange rate of the us dollar that may cause an unfavorable \r\n      foreign currency exchange impact on gilead\u2019s future revenues and pre tax \r\n      earnings; and other risks identified from time to time in gilead\u2019s \r\n      reports filed with the us securities and exchange commission the \r\n      sec in addition gilead makes estimates and judgments that affect the \r\n      reported amounts of assets liabilities revenues and expenses and \r\n      related disclosures gilead bases its estimates on historical experience \r\n      and on various other market specific and other relevant assumptions that \r\n      it believes to be reasonable under the circumstances the results of \r\n      which form the basis for making judgments about the carrying values of \r\n      assets and liabilities that are not readily apparent from other sources \r\n      there may be other factors of which gilead is not currently aware that \r\n      may affect matters discussed in the forward looking statements and may \r\n      also cause actual results to differ significantly from these estimates \r\n      further results for the quarter ended march 31 2019 are not \r\n      necessarily indicative of operating results for any future periods you \r\n      are urged to consider statements that include the words may will \r\n      would could should might believes estimates projects potential \r\n      expects plans anticipates intends continues forecast designed \r\n      goal or the negative of those words or other comparable words to be \r\n      uncertain and forward looking gilead directs readers to its press \r\n      releases annual report on form 10 k for the year ended december 31 \r\n      2018 and other subsequent disclosure documents filed with the sec \r\n      gilead claims the protection of the safe harbor contained in the private \r\n      securities litigation reform act of 1995 for forward looking statements\r\n    \r\n    \r\n\r\n      all forward looking statements are based on information currently \r\n      available to gilead and gilead assumes obligation to update or \r\n      supplement any such forward looking statements other than as required by \r\n      law any forward looking statements speak only as of the date hereof or \r\n      as of the dates indicated in the statements\r\n    \r\n    \r\n\r\n      # # #\r\n    \r\n    \r\n\r\n      gilead owns or has rights to various trademarks copyrights and trade \r\n      names used in its business including the followin$1$2gilead\u00ae \r\n      gilead sciences\u00ae ambisome\u00ae atripla\u00ae \r\n      biktarvy\u00ae cayston\u00ae complera\u00ae descovy\u00ae \r\n      emtriva\u00ae epclusa\u00ae eviplera\u00ae genvoya\u00ae \r\n      harvoni\u00ae hepsera\u00ae letairis\u00ae odefsey\u00ae \r\n      ranexa\u00ae sovaldi\u00ae stribild\u00ae truvada\u00ae \r\n      truvadaforprep\u00ae tybost\u00ae vemlidy\u00ae \r\n      viread\u00ae vosevi\u00ae yescarta\u00ae and zydelig\u00ae\r\n    \r\n    \r\n\r\n      lexiscan\u00ae is registered trademark of astellas us llc \r\n      macugen\u00ae is registered trademark of eyetech inc symtuza\u00ae \r\n      is registered trademark of janssen sciences ireland uc tamiflu\u00ae \r\n      is registered trademark of hoffmann roche inc\r\n    \r\n    \r\n\r\n      \r\nfor more information on gilead sciences inc please visit wwwgileadcom \r\n      or call the gilead public affairs department at 1 800 gilead 5 \r\n      1 800 445 3235\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gilead sciences inc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          condensed consolidated statements of income\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unaudited\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions except per share amounts\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          three months ended\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          revenues:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          product sales\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5200\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5001\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          royalty contract and other revenues\r\n        \r\n        \r\n        \r\n        \r\n          81\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          87\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total revenues\r\n        \r\n        \r\n        \r\n        \r\n          5281\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          5088\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          costs and expenses:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          cost of goods sold\r\n        \r\n        \r\n        \r\n        \r\n          957\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          1001\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          research and development expenses\r\n        \r\n        \r\n        \r\n        \r\n          1057\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          937\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          selling general and administrative expenses\r\n        \r\n        \r\n        \r\n        \r\n          1030\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          997\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total costs and expenses\r\n        \r\n        \r\n        \r\n        \r\n          3044\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          2935\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          income from operations\r\n        \r\n        \r\n        \r\n        \r\n          2237\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          2153\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          interest expense\r\n        \r\n        \r\n        \r\n        \r\n          254\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          290\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other income expense net\r\n        \r\n        \r\n        \r\n        \r\n          367\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          170\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          income before provision for income taxes\r\n        \r\n        \r\n        \r\n        \r\n          2350\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          2033\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          provision for income taxes\r\n        \r\n        \r\n        \r\n        \r\n          382\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          494\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net income\r\n        \r\n        \r\n        \r\n        \r\n          1968\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          1539\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net income loss attributable to noncontrolling interest\r\n        \r\n        \r\n        \r\n        \r\n          7\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          1\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net income attributable to gilead\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1975\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1538\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net income per share attributable to gilead common stockholders   \r\n          basic\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          155\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          118\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          shares used in per share calculation   basic\r\n        \r\n        \r\n        \r\n        \r\n          1276\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          1307\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net income per share attributable to gilead common stockholders   \r\n          diluted\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          154\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          117\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          shares used in per share calculation   diluted\r\n        \r\n        \r\n        \r\n        \r\n          1283\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          1320\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          cash dividends declared per share\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          063\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          057\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gilead sciences inc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          reconciliation of gaap to non gaap financial information\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unaudited\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions except percentages and per share amounts\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          three months ended\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          cost of goods sold reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap cost of goods sold\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          957\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1001\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 amortization of purchased intangibles\r\n        \r\n        \r\n        \r\n        \r\n          283\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          301\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          14\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          13\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap cost of goods sold\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          660\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          687\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          product gross margin reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap product gross margin\r\n        \r\n        \r\n        \r\n        \r\n          816\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          800\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 amortization of purchased intangibles\r\n        \r\n        \r\n        \r\n        \r\n          54\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          60\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          03\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          03\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap product gross margin\r\n        \r\n        \r\n        \r\n        \r\n          873\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          863\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          research and development expenses reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap research and development expenses\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1057\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          937\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          up front collaboration expenses\r\n        \r\n        \r\n        \r\n        \r\n          126\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 other costs\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          16\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          61\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          103\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other2\r\n        \r\n        \r\n        \r\n        \r\n          1\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          4\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap research and development expenses\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          871\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          814\r\n        \r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          selling general and administrative expenses reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap selling general and administrative expenses\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1030\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          997\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 other costs\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          6\r\n        \r\n        \r\n          \r\n\r\n            \r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          68\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          104\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other2\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            \u2014\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          3\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap selling general and administrative expenses\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          962\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          884\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          operating margin reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap operating margin\r\n        \r\n        \r\n        \r\n        \r\n          424\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          423\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          up front collaboration expenses\r\n        \r\n        \r\n        \r\n        \r\n          24\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 amortization of purchased intangibles\r\n        \r\n        \r\n        \r\n        \r\n          54\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          59\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 other costs\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          04\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          27\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          43\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other2\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          01\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap operating margin3\r\n        \r\n        \r\n        \r\n        \r\n          528\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          531\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other income expense net reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap other income expense net\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          367\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          170\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unrealized gains from equity securities net\r\n        \r\n        \r\n        \r\n        \r\n          197\r\n        \r\n        \r\n          \r\n        \r\n        \r\n        \r\n        \r\n          45\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap other income expense net\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          170\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          125\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gilead sciences inc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          reconciliation of gaap to non gaap financial information   \r\n          continued\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unaudited\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions except percentages and per share amounts\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          three months ended\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          effective tax rate reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap effective tax rate\r\n        \r\n        \r\n        \r\n        \r\n          163\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          243\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          up front collaboration expenses\r\n        \r\n        \r\n        \r\n        \r\n          03\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 amortization of purchased intangibles\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            10\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            %\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \r\n\r\n            23\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            %\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 other costs\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            01\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            %\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          01\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          03\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unrealized gains from equity securities net\r\n        \r\n        \r\n        \r\n        \r\n          11\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          06\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap effective tax rate3\r\n        \r\n        \r\n        \r\n        \r\n          167\r\n        \r\n        \r\n          %\r\n        \r\n        \r\n        \r\n        \r\n          228\r\n        \r\n        \r\n          %\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          net income attributable to gilead reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap net income attributable to gilead\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1975\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1538\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          up front collaboration expenses\r\n        \r\n        \r\n        \r\n        \r\n          98\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 amortization of purchased intangibles\r\n        \r\n        \r\n        \r\n        \r\n          260\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          281\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 other costs\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          18\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          117\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          160\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unrealized gains from equity securities net\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            191\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \r\n\r\n            45\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other2\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            1\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          6\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap net income attributable to gilead\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          2258\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          1958\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          diluted earnings per share reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap diluted earnings per share\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          154\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          117\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          up front collaboration expenses\r\n        \r\n        \r\n        \r\n        \r\n          008\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 amortization of purchased intangibles\r\n        \r\n        \r\n        \r\n        \r\n          020\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          021\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related \u2013 other costs\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          001\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses1\r\n        \r\n        \r\n        \r\n        \r\n          009\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          012\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unrealized gains from equity securities net\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            015\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          003\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap diluted earnings per share\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          176\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          148\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap adjustment summary:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          cost of goods sold adjustments\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          297\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          314\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          research and development expenses adjustments\r\n        \r\n        \r\n        \r\n        \r\n          186\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          123\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          selling general and administrative expenses adjustments\r\n        \r\n        \r\n        \r\n        \r\n          68\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          113\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other income expense net adjustments\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            197\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          45\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total non gaap adjustments before tax\r\n        \r\n        \r\n        \r\n        \r\n          354\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          505\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          income tax effect\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            71\r\n          \r\n        \r\n\r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          85\r\n        \r\n        \r\n          \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total non gaap adjustments after tax\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          283\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          420\r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          ____________________\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          notes:\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n1\r\n          \r\n\r\n        \r\n\r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            the period over period decrease was primarily to stock based \r\n            compensation expenses incurred in the first quarter of 2018 \r\n            associated with gilead\u2019s acquisition of kite\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n2\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          \r\n\r\n            amounts represent restructuring contingent consideration and/or \r\n            other individually insignificant amounts\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n3\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          \r\n\r\n            amounts may not sum to rounding\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gilead sciences inc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          reconciliation of gaap to non gaap 2019 full year guidance\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unaudited\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions except percentages and per share amounts\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            \r\ninitially provided\r\n\r\nfebruary 4 2019\r\n\r\nreiterated\r\n\r\nmay \r\n            2 2019\r\n          \r\n\r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          projected product gross margin gaap to non gaap reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap projected product gross margin\r\n        \r\n        \r\n        \r\n        \r\n          80%   81%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related expenses\r\n        \r\n        \r\n        \r\n        \r\n          5%   6%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap projected product gross margin1\r\n        \r\n        \r\n        \r\n        \r\n          85%   87%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          projected research and development expenses gaap to non gaap \r\n          reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap projected research and development expenses\r\n        \r\n        \r\n        \r\n        \r\n          $4195   $4480\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses\r\n        \r\n        \r\n        \r\n        \r\n          345   380\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          up front collaboration expenses\r\n        \r\n        \r\n        \r\n        \r\n          250   300\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap projected research and development expenses\r\n        \r\n        \r\n        \r\n        \r\n          $3600   $3800\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          projected selling general and administrative expenses gaap to \r\n          non gaap reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap projected selling general and administrative expenses\r\n        \r\n        \r\n        \r\n        \r\n          $4255   $4490\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses\r\n        \r\n        \r\n        \r\n        \r\n          355   390\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap projected selling general and administrative expenses\r\n        \r\n        \r\n        \r\n        \r\n          $3900   $4100\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          projected effective tax rate gaap to non gaap reconciliation:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gaap projected effective tax rate 2\r\n        \r\n        \r\n        \r\n        \r\n          215%   225%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          tax rate effect of adjustments noted above 2\r\n        \r\n        \r\n        \r\n        \r\n          15%   15%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          non gaap projected effective tax rate\r\n        \r\n        \r\n        \r\n        \r\n          200%   210%\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          projected diluted eps impact of acquisition related up front \r\n          collaboration stock based compensation and other expenses2:\r\n        \r\n        \r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          acquisition related expenses / up front collaboration expenses\r\n        \r\n        \r\n        \r\n        \r\n          $093   $097\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stock based compensation expenses\r\n        \r\n        \r\n        \r\n        \r\n          $047   $053\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          projected diluted eps impact of acquisition related up front \r\n          collaboration stock based compensation and other expenses2\r\n        \r\n        \r\n        \r\n        \r\n          $140   $150\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          ____________________\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            notes:\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n1\r\n          \r\n\r\n        \r\n\r\n        \r\n          \u00a0\r\n        \r\n        \r\n          total stock based compensation expenses have less than one percent \r\n          impact on non gaap projected product gross margin\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n2\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          excludes fair value adjustments of equity securities and the \r\n          associated income tax effect as gilead is unable to project future \r\n          fair value adjustments and other discrete tax charges or benefits\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gilead sciences inc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          condensed consolidated balance sheets\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unaudited\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n        \r\n        \r\n        \r\n          december 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          cash cash equivalents and marketable securities\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          30125\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          31512\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          accounts receivable net\r\n        \r\n        \r\n        \r\n        \r\n          3283\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          3327\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          inventories\r\n        \r\n        \r\n        \r\n        \r\n          898\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          814\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          property plant and equipment net\r\n        \r\n        \r\n        \r\n        \r\n          4116\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          4006\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          intangible assets net\r\n        \r\n        \r\n        \r\n        \r\n          15438\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          15738\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          goodwill\r\n        \r\n        \r\n        \r\n        \r\n          4117\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          4117\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other assets\r\n        \r\n        \r\n        \r\n        \r\n          4860\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          4161\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total assets\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          62837\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          63675\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          current liabilities\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          9397\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          10605\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          long term liabilities\r\n        \r\n        \r\n        \r\n        \r\n          31349\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          31536\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stockholders\u2019 equity1\r\n        \r\n        \r\n        \r\n        \r\n          22091\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          21534\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total liabilities and stockholders\u2019 equity\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          62837\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          63675\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          ____________________\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            note:\r\n          \r\n        \r\n\r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            \u00a0\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n1\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          as of march 31 2019 there were 1274 million shares of common \r\n          stock issued and outstanding\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gilead sciences inc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          product sales summary\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unaudited\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          three months ended\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          atripla \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          133\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          228\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          atripla \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          16\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          51\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          atripla \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          22\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          35\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          171\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          314\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          biktarvy \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          739\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          35\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          biktarvy \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          48\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          biktarvy \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          6\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          793\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          35\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          complera / eviplera \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          44\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          67\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          complera / eviplera \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          62\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          109\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          complera / eviplera \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          9\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          14\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          115\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          190\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          descovy \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          233\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          274\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          descovy \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          68\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          75\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          descovy \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          41\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          12\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          342\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          361\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          genvoya \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          728\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          853\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          genvoya \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          193\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          186\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          genvoya \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          94\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          43\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          1015\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          1082\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          odefsey \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          282\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          279\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          odefsey \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          106\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          58\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          odefsey \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          9\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          5\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          397\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          342\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stribild \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          67\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          133\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stribild \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          18\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          29\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          stribild \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          11\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          12\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          96\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          174\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          truvada \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          551\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          507\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          truvada \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          33\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          97\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          truvada \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          22\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          48\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          606\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          652\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other hiv1 \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          11\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          9\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other hiv1 \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          1\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          1\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other hiv1 \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          5\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          3\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          17\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          13\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          revenue share \u2013 symtuza2 \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          42\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u2014\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          revenue share \u2013 symtuza2 \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          24\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          7\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          66\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          7\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total hiv \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          2830\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          2385\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total hiv \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          569\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          613\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total hiv \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          219\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          172\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          3618\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          3170\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          ambisome \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          8\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          17\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          ambisome \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n          57\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          56\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          ambisome \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          28\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          34\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          93\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          107\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          gilead sciences inc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          product sales summary   continued\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          unaudited\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          in millions\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          three months ended\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          march 31\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          2019\r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          2018\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          ledipasvir/sofosbuvir3 \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          117\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          234\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          ledipasvir/sofosbuvir3 \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          27\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          56\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          ledipasvir/sofosbuvir3 \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          81\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          58\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          225\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          348\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          letairis \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          197\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          204\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          ranexa \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          155\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          195\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          sofosbuvir/velpatasvir4 \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          230\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          269\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          sofosbuvir/velpatasvir4 \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          154\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          198\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          sofosbuvir/velpatasvir4 \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          107\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          69\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          491\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          536\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          vemlidy \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          65\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          47\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          vemlidy \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          4\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          3\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          vemlidy \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          32\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          8\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          101\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          58\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          viread \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          12\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          7\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          viread \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          14\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          30\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          viread \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          46\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          60\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          72\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          97\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          vosevi \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            45\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            86\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          vosevi \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            16\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            16\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          vosevi \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            2\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            5\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            63\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            107\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          yescarta \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            90\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            40\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          yescarta \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            6\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            \u2014\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          yescarta \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            \u2014\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            \u2014\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            96\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            40\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          zydelig \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            11\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            14\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          zydelig \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            15\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            18\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          zydelig \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            1\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            1\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            27\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            33\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other5 \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            36\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            29\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other5 \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            20\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            15\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          other5 \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            6\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            62\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            62\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            106\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total product sales \u2013 us\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            3796\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            3527\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total product sales \u2013 europe\r\n        \r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            882\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n        \r\n          \r\n\r\n            1005\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          total product sales \u2013 other international\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            522\r\n          \r\n        \r\n\r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n        \r\n          \r\n\r\n            469\r\n          \r\n        \r\n\r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5200\r\n        \r\n        \r\n        \r\n        \r\n          $\r\n        \r\n        \r\n          5001\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n      \r\n\r\n        \r\n\r\n          ____________________\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          notes:\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n1\r\n          \r\n\r\n        \r\n\r\n        \r\n          \u00a0\r\n        \r\n        \r\n          includes emtriva and tybost\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n2\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          represents gilead\u2019s revenue from cobicistat c emtricitabine ftc \r\n          and tenofovir alafenamide taf in symtuza darunavir/c/ftc/taf \r\n          fixed dose combination product commercialized by janssen sciences \r\n          ireland uc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n3\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          amounts consist of sales of harvoni and the authorized generic \r\n          version of harvoni sold by gilead\u2019s separate subsidiary asegua \r\n          therapeutics llc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n4\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          amounts consist of sales of epclusa and the authorized generic \r\n          version of epclusa sold by gilead\u2019s separate subsidiary asegua \r\n          therapeutics llc\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n          \r\n\r\n            \r\n5\r\n          \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n          includes cayston hepsera and sovaldi\r\n        \r\n      \r\n\r\n      \r\n\r\n        \r\n\r\n        \r\n        \r\n        \r\n        \r\n          \u00a0\r\n        \r\n      \r\n\r\n    \r\n\r\n    \r\n\r\n    \r\n\r\n  \r\n\r\n\r\n\r\n\r\nview source version on businesswireco$1$2https://wwwbusinesswirecom/news/home/20190502005790/en/\r\n\r\n    \r\n\r\n      \r\ninvestors\r\nrobin washington650 522 5688\r\nsung \r\n      lee650 524 7792\r\n\r\nmedia\r\namy \r\n      flood650 522 5643\r\n    \r\n    \r\n\r\n    \r\n\r\n  \r\n\r\npermalin$1$2http://wwwbusinesswirecom/news/home/20190502005790/en", "titolo_articolo": "gilead sciences announces first quarter 2019 financial results", "tags": []}